Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome (HMS4)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study was to investigate from 3 sites (University of Connecticut, University of Florida, and University of California, Irvine) whether enhancement of a modified Mediterranean-style, low glycemic load diet (MED) with specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED) could improve cardiometabolic risk factors in women with metabolic syndrome.
| Condition | Intervention |
|---|---|
|
Metabolic Syndrome Overweight Obesity Hypercholesterolemia |
Dietary Supplement: UltraMealPlus 360 (Medical food) Other: Low-glycemic-load diet |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Multi-center, Randomized Intervention to Compare the Effects of 2 Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome |
- TG-to-HDL ratio [ Time Frame: Baseline, 8 weeks, 12 weeks ] [ Designated as safety issue: No ]
- Components of metabolic syndrome (TG, HDL, resolution of MetS) [ Time Frame: Baseline, 8 weeks, 12 weeks ] [ Designated as safety issue: No ]
- Glucose intolerance (fasting glucose/insulin, leptin, HbA1c, HOMA score) [ Time Frame: Baseline, 8 weeks, 12 weeks ] [ Designated as safety issue: No ]
- CVD risk factors (cholesterol, LDL, chol/HDL, apoAI, apoB, apoAII, apoCII, apoCIII, apoE, homocysteine, RBC fatty acids, Framingham risk score) [ Time Frame: Baseline, 8 weeks, 12 weeks ] [ Designated as safety issue: No ]
- Inflammatory cytokines (TNF-alpha, IL-6, sICAM, sVCAM, MCP1) [ Time Frame: Baseline, 8 weeks, 12 weeks ] [ Designated as safety issue: No ]
- Body composition (weight, BMI, % body fat, % lean mass, waist-to-hip ratio, DEXA scanning) [ Time Frame: Baseline, 8 weeks, 12 weeks ] [ Designated as safety issue: No ]
- Subjective assessment (MOS-MCS/PCS questionnaires, VAS-satiety/craving questionnaires) [ Time Frame: baseline, then every 2 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 89 |
| Study Start Date: | August 2008 |
| Study Completion Date: | April 2010 |
| Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Low-glycemic-load diet
Modified Mediterranean-style low-glycemic-load diet
|
Other: Low-glycemic-load diet
Modified Mediterranean-style low-glycemic-load diet
|
|
Experimental: Low-glycemic-load diet + medical food
Modified Mediterranean-style, low-glycemic-load diet + medical food
|
Dietary Supplement: UltraMealPlus 360 (Medical food)
Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
Other Name: UltraMealPlus 360
Other: Low-glycemic-load diet
Modified Mediterranean-style low-glycemic-load diet
|
Detailed Description:
As the worldwide dietary pattern becomes more westernized, the metabolic syndrome is reaching epidemic proportions. Lifestyle modifications including diet and exercise are recommended as first-line intervention for treating metabolic syndrome. Previously, we reported that specific phytochemical supplementation for 12 weeks (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins) increased the effectiveness of the modified Mediterranean-style low glycemic load dietary program on variables associated with metabolic syndrome and CVD in subjects with metabolic syndrome and elevated LDL cholesterol. In this study, we propose to conduct a multi-center randomized trial to confirm our previous findings.
Eligibility| Ages Eligible for Study: | 20 Years to 75 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- BMI ≥25 and <45
- LDL >100 mg/dl
- TG ≥150 and <400 mg/dl
meet 2 or more of the following 4 criteria:
- HDL <50 mg/dl
- blood pressure ≥130/85 mmHg (or diagnosed hypertension on medication)
- fasting glucose ≥100 mg/dl and <150 mg/dl
- waist circumference >35 inches
Exclusion Criteria:
Medical History and Concurrent Diseases
- Over the preceding 4 weeks, initiation or cessation of regular exercise
- Over the preceding 4 weeks, involvement in a significant diet or weight loss program such as Atkin's diet program, a very low calorie liquid program (such as Optifast, Medifast, and HMR), or any diet that has led to a weight loss of 10% of body weight over a period of 6 weeks
- Use of blood sugar lowering medications including thiazolidinedione class of oral medications including Avandia (rosiglitazone), Avandamet (metformin/rosiglitazone), Actos (pioglitazone), metformin (Glucophage, Fortamet, Riomet) or insulin over the preceding 12 weeks
- Over the preceding 4 weeks, regular use of Kaprex® or Kaprex AI® at least 3 days/week
- Over the preceding 4 weeks, regular use of NSAIDs (i.e. ibuprofen, celecoxib, etc.) at least 3 days per week
- Over the preceding 12 weeks, use of cholesterol lowering medications, either by prescription (statins, etc.) or over-the-counter (gugulipids, niacin, etc.)
- Over the preceding 12 weeks, use of oral or injectable corticosteroids, such as prednisone
- Current use of oral anticoagulants such as Coumadin or injectable anticoagulants such as Heparin or Low Molecular Weight Heparin
- Use of electronic implants such as pacemakers, defibrillators, nerve stimulators
- Allergy to one or more of the ingredients in the investigational products
- Poorly controlled hypertension (blood pressure above 155/95)
- History of significant liver or kidney disease (recent or ongoing hepatitis, cirrhosis, glomerulonephritis, dialysis treatment, etc.)
- History of serious heart disease (heart attack, angina, cardiac surgery, arrhythmia, or congestive heart failure)
- History of deep vein thrombosis or pulmonary embolus (blood clot to lungs)
- History of autoimmune diseases such as inflammatory bowel disease (Crohn's disease, and/or ulcerative colitis), multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, polymyositis, scleroderma and thyroiditis
- History of eating disorder (anorexia nervosa or bulimia) in preceding 5 years
- History of alcoholism or drug addiction in the preceding 5 years
- History of serious mental illness
- History of attempted suicide in past 10 years
- Untreated endocrine, neurological, or infectious disorder
- Diagnosis of Human Immunodeficiency Virus (HIV) or Acquired HIV (AIDS)
- Current cancer or a history of cancer (except skin cancer)
- Pregnancy or lactation
- If female of childbearing potential, unwillingness to practice a reliable method of birth control (i.e. physical sperm barriers or hormonal therapies)
- Any other sound medical, psychiatric and/or social reason as determined by the Principal Investigator (PI).
Physical and Laboratory Test Findings
- TG ≥ 400 mg/dl
- abnormal blood count (Hct < 30 or > 47%, WBC < 3,000 or > 12,000, platelets <140 or > 500)
- abnormal kidney function test(s) (BUN > 30 mg/dL or creatinine > 1.5 mg/dL) or liver function test(s) (bilirubin total > 2.0 mg/dL, ALT > 75 IU/L, AST > 75 IU/L; Alk Phos > 130 IU)
- fasting glucose >150 mg/dL, serum calcium (>10.5 mg/dL), positive pregnancy test (ß-hCG in blood)
Contacts and Locations| United States, Florida | |
| Mark McIntosh MD | |
| Jacksonville, Florida, United States, 32209 | |
| Study Director: | Robert H Lerman, MD/PhD | MetaProteomics LLC |
| Principal Investigator: | Mark McIntosh, MD | University of Florida |
| Principal Investigator: | Maria Luz Fernandez, PhD | University of Connecticut |
| Principal Investigator: | Wadie Najm, PhD | University of California at Irvine |
More Information
Publications:
| Responsible Party: | MetaProteomics LLC |
| ClinicalTrials.gov Identifier: | NCT01010841 History of Changes |
| Other Study ID Numbers: | HMS4-MUL-CT |
| Study First Received: | November 6, 2009 |
| Last Updated: | January 11, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by MetaProteomics LLC:
|
Metabolic syndrome Serum lipid Dietary intervention Lifestyle modification Glycemic load |
Phytochemical Hops Acacia Mediterranean diet Kinase modulator |
Additional relevant MeSH terms:
|
Hypercholesterolemia Obesity Overweight Metabolic Syndrome X Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases |
Overnutrition Nutrition Disorders Body Weight Signs and Symptoms Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders |
ClinicalTrials.gov processed this record on May 19, 2013